BioCorRx (BICX) Gains from Investment Securities (2015 - 2025)

BioCorRx has disclosed Gains from Investment Securities across 10 years of filings, most recently posting $1.6 million for Q3 2025.

• Gains from Investment Securities for Q3 2025 came in at $1.6 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $1.6 million (changed N/A YoY), and the FY2025 annual result was $1.7 million, up 21.61% from the prior year.
• Gains from Investment Securities came in at $1.6 million for Q3 2025 at BioCorRx, up from $1.5 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $1.6 million in Q3 2025 to a low of $818631.0 in Q2 2021.
• The 4-year median for Gains from Investment Securities is $858101.0 (2022), against an average of $1.0 million.
• Peak annual rise in Gains from Investment Securities reached 1029.15% in 2021, while the deepest fall reached 1.5% in 2021.
• BioCorRx's Gains from Investment Securities stood at $818631.0 in 2021, then gained by 4.82% to $858101.0 in 2022, then advanced by 3.89% to $891443.0 in 2023, then soared by 80.61% to $1.6 million in 2025.
• The last three Gains from Investment Securities figures came in at $1.6 million (Q3 2025), $1.5 million (Q2 2025), and $891443.0 (Q3 2023), per Business Quant data.